Skip to main content
Top
Published in: Cancer Causes & Control 5/2019

01-05-2019 | Non-Hodgkin Lymphoma | Original Paper

Global patterns and trends in the incidence of non-Hodgkin lymphoma

Authors: Adalberto Miranda-Filho, Marion Piñeros, Ariana Znaor, Rafael Marcos-Gragera, Eva Steliarova-Foucher, Freddie Bray

Published in: Cancer Causes & Control | Issue 5/2019

Login to get access

Abstract

Purpose

Despite an increasing understanding of the pathology and genetics of non-Hodgkin lymphoma (NHL), global reports on variations in the incidence of NHL remain limited in their number and scope.

Methods

To provide a situation analysis, national incidence estimates for NHL in 185 countries for the year 2018 were obtained from the GLOBOCAN database. We also used recorded incidence data from Cancer Incidence in Five Continents (CI5) plus for years of diagnosis 1980–2012 to examine temporal trends.

Results

NHL ranked as the 5th to 9th most common cancer in most countries worldwide, with almost 510,000 new cases estimated in 2018. Observed incidence rates of NHL 2008–2012 varied markedly by world region: among males, rates were highest among Israel Jews [age-standardized (world) rate of 17.6 per 100,000), Australia (15.3), US whites (14.5), Canada (13.7), and Portugal (13.3)]. Where data were available, most populations exhibited stable or slightly increasing incidence rates; in North America, parts of Europe, and Oceania the rising incidence rates were generally observed until the 1990s, with a stabilization seen thereafter.

Conclusion

Marked variations in NHL incidence rates remain in populations in each world region. Special attention should be given to further etiological research on the role of endemic infections and environmental exposures, particularly in Africa, Asia, and Latin America. To permit internationally comparable statistics, an equal focus on addressing the quality of hematological information in population-based registries is also warranted.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Weltgesundheitsorganisation (2017). WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) World Health Organization classification of tumours. International Agency for Research on Cancer, Lyon, p 585 Weltgesundheitsorganisation (2017). WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) World Health Organization classification of tumours. International Agency for Research on Cancer, Lyon, p 585
3.
go back to reference Armitage JO, Gascoyne RD, Lunning MA, Cavalli F (2017) Non-Hodgkin lymphoma. Lancet 390(10091):298–310CrossRefPubMed Armitage JO, Gascoyne RD, Lunning MA, Cavalli F (2017) Non-Hodgkin lymphoma. Lancet 390(10091):298–310CrossRefPubMed
5.
go back to reference Boffetta P (2011) I. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol 22(Supplement 4):iv27–iv31CrossRef Boffetta P (2011) I. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol 22(Supplement 4):iv27–iv31CrossRef
6.
go back to reference Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391(10125):1023–1075CrossRefPubMedPubMedCentral Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391(10125):1023–1075CrossRefPubMedPubMedCentral
7.
go back to reference Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF et al (2014) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014(48):130–144CrossRefPubMedPubMedCentral Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF et al (2014) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014(48):130–144CrossRefPubMedPubMedCentral
8.
go back to reference Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S (2016) Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 4(9):e609–e616CrossRefPubMed Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S (2016) Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 4(9):e609–e616CrossRefPubMed
10.
go back to reference Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA (2014) Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS 28(15):2313–2318CrossRefPubMedPubMedCentral Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA (2014) Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS 28(15):2313–2318CrossRefPubMedPubMedCentral
11.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed
14.
go back to reference Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay J (eds) (2017) Cancer incidence in five continents, Vol. XI (electronic version). International Agency for Research on Cancer, Lyon. Available from: http://ci5.iarc.fr. Accessed 20 Aug 2018 Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay J (eds) (2017) Cancer incidence in five continents, Vol. XI (electronic version). International Agency for Research on Cancer, Lyon. Available from: http://​ci5.​iarc.​fr. Accessed 20 Aug 2018
15.
17.
go back to reference Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–1957). Tohoku University School of Medicine, Sendai Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–1957). Tohoku University School of Medicine, Sendai
18.
go back to reference Jensen OM, International Agency for Research on Cancer, World Health Organization, International Association of Cancer Registries (eds) (1991) Cancer registration: principles and methods, IARC scientific publications. International Agency for Research on Cancer, Lyon, p 288 Jensen OM, International Agency for Research on Cancer, World Health Organization, International Association of Cancer Registries (eds) (1991) Cancer registration: principles and methods, IARC scientific publications. International Agency for Research on Cancer, Lyon, p 288
19.
go back to reference R Development Core Team. R Development Core Team (2014) R: a language and environment for statistical computing (computer programme). R Foundation for Statistical Computing, Vienna R Development Core Team. R Development Core Team (2014) R: a language and environment for statistical computing (computer programme). R Foundation for Statistical Computing, Vienna
20.
go back to reference Østgård LSG, Nørgaard M, Nørgaard JM, Severinsen MT, Sengeløv H, Friis LS et al (2013) Data quality in the Danish national acute leukemia registry: a hematological data resource. Clin Epidemiol 5:335CrossRefPubMedPubMedCentral Østgård LSG, Nørgaard M, Nørgaard JM, Severinsen MT, Sengeløv H, Friis LS et al (2013) Data quality in the Danish national acute leukemia registry: a hematological data resource. Clin Epidemiol 5:335CrossRefPubMedPubMedCentral
21.
go back to reference McKay P, Fielding P, Gallop-Evans E, Hall GW, Lambert J, Leach M et al (2016) Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. Br J Haematol 172(1):32–43CrossRefPubMed McKay P, Fielding P, Gallop-Evans E, Hall GW, Lambert J, Leach M et al (2016) Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. Br J Haematol 172(1):32–43CrossRefPubMed
22.
go back to reference Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T et al (2014) Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin study group. Blood 123(11):1658–1664CrossRefPubMed Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T et al (2014) Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin study group. Blood 123(11):1658–1664CrossRefPubMed
24.
go back to reference Weltgesundheitsorganisation, Swerdlow SH, International Agency for Research on Cancer (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues: [… reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25–27, 2007, World Health Organization classification of tumours, 4 edn. International Agency for Research on Cancer, Lyon. p 439 Weltgesundheitsorganisation, Swerdlow SH, International Agency for Research on Cancer (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues: [… reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25–27, 2007, World Health Organization classification of tumours, 4 edn. International Agency for Research on Cancer, Lyon. p 439
25.
go back to reference Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM (2016) EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management: EBV+ DLBCL 2016 update. Am J Hematol 91(5):529–537CrossRefPubMed Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM (2016) EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management: EBV+ DLBCL 2016 update. Am J Hematol 91(5):529–537CrossRefPubMed
26.
go back to reference Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefPubMedPubMedCentral Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefPubMedPubMedCentral
27.
go back to reference Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G et al (2015) Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 163(7):507–518CrossRefPubMedPubMedCentral Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G et al (2015) Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 163(7):507–518CrossRefPubMedPubMedCentral
28.
go back to reference Chaabna K, Bray F, Wabinga HR, Chokunonga E, Borok M, Vanhems P et al (2013) Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence?: trends of KS incidence in Zimbabwe and Uganda. Int J Cancer 133(5):1197–1203CrossRefPubMed Chaabna K, Bray F, Wabinga HR, Chokunonga E, Borok M, Vanhems P et al (2013) Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence?: trends of KS incidence in Zimbabwe and Uganda. Int J Cancer 133(5):1197–1203CrossRefPubMed
29.
go back to reference Parkin DM, Garcia-Giannoli H, Raphael M, Martin A, Katangole-Mbidde E, Wabinga H et al (2000) Non-Hodgkin lymphoma in Uganda: a case–control study. AIDS 14(18):2929–2936(CrossRefPubMed Parkin DM, Garcia-Giannoli H, Raphael M, Martin A, Katangole-Mbidde E, Wabinga H et al (2000) Non-Hodgkin lymphoma in Uganda: a case–control study. AIDS 14(18):2929–2936(CrossRefPubMed
30.
go back to reference Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536–545CrossRefPubMed Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536–545CrossRefPubMed
31.
go back to reference Engels EA, Cho ER, Jee SH (2010) Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 11(9):827–834CrossRefPubMedPubMedCentral Engels EA, Cho ER, Jee SH (2010) Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 11(9):827–834CrossRefPubMedPubMedCentral
32.
go back to reference Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim J-J et al (2013) Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med 28(4):413–419CrossRefPubMedPubMedCentral Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim J-J et al (2013) Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med 28(4):413–419CrossRefPubMedPubMedCentral
33.
go back to reference Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I et al (2000) Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer 85(3):319–324CrossRefPubMed Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I et al (2000) Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer 85(3):319–324CrossRefPubMed
34.
go back to reference Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24(39):6058–6068CrossRefPubMed Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24(39):6058–6068CrossRefPubMed
35.
go back to reference Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M et al (2016) Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica 101(10):1244–1250CrossRefPubMedPubMedCentral Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M et al (2016) Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica 101(10):1244–1250CrossRefPubMedPubMedCentral
36.
go back to reference van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS et al (2014) Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006: lymphoid neoplasms in Australia 1982–2006. Int J Cancer 135(9):2146–2156CrossRefPubMed van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS et al (2014) Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006: lymphoid neoplasms in Australia 1982–2006. Int J Cancer 135(9):2146–2156CrossRefPubMed
37.
go back to reference Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I et al (2010) Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol 21(Suppl 3):iii90–iii96PubMed Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I et al (2010) Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol 21(Suppl 3):iii90–iii96PubMed
38.
go back to reference Adamson P, Bray F, Costantini AS, Tao M-H, Weiderpass E, Roman E (2007) Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 43(2):391–401CrossRefPubMed Adamson P, Bray F, Costantini AS, Tao M-H, Weiderpass E, Roman E (2007) Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 43(2):391–401CrossRefPubMed
39.
go back to reference Clarke CA, Glaser SL (2002) Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94(7):2015–2023CrossRefPubMed Clarke CA, Glaser SL (2002) Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94(7):2015–2023CrossRefPubMed
Metadata
Title
Global patterns and trends in the incidence of non-Hodgkin lymphoma
Authors
Adalberto Miranda-Filho
Marion Piñeros
Ariana Znaor
Rafael Marcos-Gragera
Eva Steliarova-Foucher
Freddie Bray
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 5/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01155-5

Other articles of this Issue 5/2019

Cancer Causes & Control 5/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine